Iniciar sesión Regístrese gratis

180 Life Sciences Retorno sobre activos

¿Qué es el Retorno sobre activos de 180 Life Sciences?

El Retorno sobre activos de 180 Life Sciences Corp. es -285.72%

¿Cuál es la definición de Retorno sobre activos?



El rendimiento de los activos indica cuál rentables son los activos de una empresa para generar ingresos. Se calcula dividiendo la utilidad neta por el promedio de los activos totales.

The return on assets (ROA) tells you what the company can do with what it has, i.e. how many dollars of earnings they derive from each dollar of assets they control. It's a useful number for comparing competing companies in the same industry. The number will vary widely across different industries. Return on assets gives an indication of the capital intensity of the company, which will depend on the industry; companies that require large initial investments will generally have lower return on assets. ROAs over 5% are generally considered good.

Retorno sobre activos de compañías en Sector Health Care en NASDAQ en comparadas con 180 Life Sciences

¿Qué hace 180 Life Sciences?

180 Life Sciences Corp., a clinical-stage biotechnology company, engages in the development of novel drugs for unmet medical needs in chronic pain, inflammation, inflammatory diseases, and fibrosis. Its product development platforms in Phase IIb/III clinical trials include Fibrosis and anti-tumour necrosis factor (Anti-TNF) platform, which focuses on fibrosis and Anti-TNF; Synthetic Cannabidiol (CBD) Analogs platform, which are man-made derivatives of CBD; and a7nAChR platform, which focuses on alpha 7 nicotinic acetylcholine receptor. The company was incorporated in 2016 and is headquartered in Palo Alto, California.

Empresas con retorno sobre activos similar a 180 Life Sciences